Products
Sonelokimab Biosimilar Bispecific Biologic (IL-17A / IL-17F / Albumin) for Research
Cat No.: GMP-Bios-INN-996
Pre-made Sonelokimab benchmark antibody (Bispecific, anti-ALB;IL17A/IL17;IL17F therapeutic antibody, Anti-FDAHT/HSA/PRO0883/PRO0903/PRO1341;CTLA-8/CTLA8/IL-17A/ILA17;CANDF6/ML-1/ML1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-996-1mg | 1mg | |
| GMP-Bios-INN-996-10mg | 10mg | |
| GMP-Bios-INN-996-100mg | 100mg | |
| GMP-Bios-INN-996-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Sonelokimab Biosimilar, Bispecific, Anti-ALB;IL17A/IL17;IL17F Antibody: Anti-FDAHT/HSA/PRO0883/PRO0903/PRO1341;CTLA-8/CTLA8/IL-17A/ILA17;CANDF6/ML-1/ML1 therapeutic antibody |
| INN Name | Sonelokimab |
| Target | ALB;IL17A/IL17;IL17F |
| Format | Bispecific |
| Derivation | |
| Species Reactivity | |
| CH1 Isotype | |
| VD LC | |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech |
